The Pharmacy Times® C. Difficile Resource Center is a comprehensive resource for clinical news and expert insights on issues related to Clostridium difficile, a bacteria that causes colitis, a serious inflammation of the colon.
March 14th 2024
Antimicrobial stewardship efforts focusing on accurate penicillin allergy histories, β-lactam cross-reactivity education, and guideline-driven narrow-spectrum prescribing may help sustainably decrease health care–associated Clostridioides difficile infection rates.
FDA Approves First-in-Class Microbiota-Based Live Biotherapeutic for C. Difficile Infection
December 1st 2022Live-jslm (Rebyota; Ferring Pharmaceuticals) is indicated for the prevention of recurring Clostridioides difficile infection among patients 18 years of age and older after an antibiotic treatment.
Read More
Unmet Needs in Management of C. Difficile Infection (CDI)
Bincy Abraham, MD, MS; Thomas Lodise, PharmD, PhD; Teena Chopra, MD, MPH; and Paul Feuerstadt, MD, share unmet needs, including access to therapies, in treatment of C. difficile infection (CDI).
Watch
Differences between Fecal Microbiota Transplantation Studies to Treat C. difficile Infection (CDI)
Experts discuss differences in designs of clinical trials of 4 emerging microbiota-based live biotherapeutics - RBX2660, SER-109, CP101, VE303, for treatment of rCDI.
Watch
SER-109, CP101, VE303 for Treatment of Recurrent C. difficile Infection (rCDI)
Drs Abraham and Feuerstadt share recent data with emerging live biotherapeutic products, SER-109, CP101, and VE303, for treatment of recurrent C difficile infection (rCDI).
Watch
RBX2660 for Treatment of Recurrent C. difficile Infection (rCDI)
Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.
Watch
Challenges with Current Treatments and Emerging Treatments for C. difficile Infection (CDI)
Drs Chopra and Feuerstadt summarize challenges with current treatments and discuss live biotherapeutic products that are being studied for recurrent C difficile infection (rCDI).
Watch
Foundational Trials for Fecal Microbiota Transplantation for C. difficile Infection
Dr Lodise summarizes foundational trials that led to the use of fecal microbiota transplant for the treatment of rCDI.
Watch
Fecal Microbiota Transplantation (FMT) for Treatment of C. difficile Infection (CDI)
Drs Tom Lodise and Bincy Abraham provide an overview of fecal microbiota transplantation and long-term safety of FMT use.
Watch
Long-Term Impact of C. difficile Infection (CDI) and Infection Recurrence
A gastroenterologist reviews the long-term impact of dysbiosis and Clostridioides difficile infection.
Watch